Pfizer Inc - aktuální graf a vývoj ceny
Here's Why the Best Is Yet to Come for Pfizer Inc.
Here's Why the Best Is Yet to Come for Pfizer Inc. Motley Fool - May 14, 2017 The company's acquisitions have added more likely winners. Pfizer bought Anacor in 2016, picking up atopic dermatitis drug Eucrisa, which won FDA approval in December.14. 05. 2017
3 Reasons Pfizer, Inc. Investors Shouldn't Be Concerned About the Q1 Revenue Dip
3 Reasons Pfizer, Inc. Investors Shouldn't Be Concerned About the Q1 Revenue Dip Motley Fool - May 2, 2017 Pfizer, Inc. (NYSE:PFE) reported its first-quarter results before the market opened on Tuesday. The big drugmaker's revenue of .8 billion reflected a 2% drop from the prior-year period. Pfizer beats - Business Insider Pfizer beats 1Q profit forecasts - Seattle Times02. 05. 2017
Pfizer: There Is No Upside Without M&A
Pfizer: There Is No Upside Without M&A Seeking Alpha - May 16, 2017 Thus, in this article, I will focus on a quantitative valuation of the company without taking into account any potential M&A that Pfizer could announce in 2017/2018, which looks unpredictable, to assess if there is any upside in the company, as ...16. 05. 2017